Safety of formoterol in children and adolescents: experience from asthma clinical trials
Background The safety of long-acting beta(2) agonist (LABA) therapy in asthma remains controversial but no large scale analyses have been published of LABA safety in children. Methods The frequency of asthma-related deaths and hospitalisations following formoterol use in children (4-11 years) and adolescents (12-17 years), compared with non-LABA treatment, was assessed in all AstraZeneca-sponsored